Table 2 Laboratory findings on admission and presence of the comorbidities in the study population by ESRD status

From: The risk factors associated with COVID-19-Related death among patients with end‐stage renal disease

Characteristics ESRD
Median (IQRa)
Non- ESRD
Median (IQRa)
P-value
WBC count, × 109 per L, 9.4 (6.5–14.0) 8.1 (5.6–11.1) 0.058
Lymphocyte count,× 109/L 1.51(0.98–2.23) 2.00 (1.21–2.80) 0.065
Neutrophils, ×109/L 7.9 (7.06–8.8) 7.3 (6.3–8.1) 0.005
Hb, g/dL 11.8 (9.4–13.7) 13.1 (11.8–14.6) 0.008
RBC, million/mm3 3.87 (3.16–4.55) 4.63 (4.25–5.16) < 0.001
Platelet counts, ×103/Ml 188.5(139.5-240.5) 213.0 (165.0-264.5) 0.224
AST, U/L 32 (22–51) 34 (25–49) 0.897
ALT, U/L 27 (18–37) 26 (18–44) 0.569
Creatinine, mg/dl 6.1 (4.5–8.4) 1.0 (0.8–1.3) < 0.001
PT, s 14.0 (13.5–16.0) 13.5 (13.0–14.0) 0.004
ESR, mm/h 54.0 (26.0-74.5) 35.5 (19.0–64.0) < 0.009
CRP, mg/l 25.0 (4.0–75.0) 15.7 (3.1–61.5) 0.047
LDH, U/L 461 (374–732) 405 (329–549) 0.226
CPK, U/L 76.0 (45.0-237.0) 73.5 (14.3–135.7) 0.802
Sodium (Na), mmol/L 135 (130–139) 136 (133–138) 0.265
Potassium (K), mmol/L 5.0 (4.4–5.3) 4.2 (3.9–4.5) < 0.001
  1. ESRD End-Stage Renal Disease, ALT Alanine transaminases, AST Aspartate transaminases, CRP C-reactive protein, CPK Creatine phosphokinase, ESR Erythrocyte Sedimentation Rate, Hb Hemoglobin, LDH Lactate Dehydrogenase, PT Prothrombin Time, RBC Red Blood Cell, WBC White Blood Cell
  2. aIQR Inter quartile range